BioBDx to Present at the 2012 BioPharm America and AdvaMed MedTech Conferences in Boston
PLYMOUTH MEETING, Pa., Sept. 17, 2012 /PRNewswire/ -- BioBehavioral Diagnostics (BioBDx) announced today that Calvin Sumner M.D., chief medical officer and SVP of clinical development, will be presenting at the BioPharm America Conference taking place September 19-21, 2012 and Byron Hewett, chairman and CEO, will be presenting at the AdvaMed MedTech Conference taking place October 1-3, 2012, both in Boston, MA.
BioBDx manufactures and markets the Quotient® System, a tool that objectively measures brain functions related to deficits in response inhibition. The first FDA-cleared application of this platform technology is the objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of attention-deficit hyperactivity disorder (ADHD).
Dr. Sumner and Mr. Hewett will provide a company overview and update on the Quotient System during their presentations:
|
Event: |
BioPharm America 2012 Conference | |
|
Date: |
Friday, September 21, 2012 | |
|
Time: |
10:25 am ET | |
|
Location: |
Hancock Room; Westin Boston Waterfront | |
|
Event: |
AdvaMed 2012 MedTech Conference | |
|
Date: |
Tuesday, October 2, 2012 | |
|
Time: |
11:10 am ET | |
|
Location: |
Room 051; Boston Convention & Exhibition Center |
About the Quotient® ADHD Test
The Quotient® ADHD Test measures motion and analyzes shifts in attention state to give an objective picture of the core symptom areas of ADHD. Clinicians use the Quotient® ADHD Test at the initial visit to assess severity of the three core symptoms of ADHD; hyperactivity, inattention and impulsivity. Patients may be re-assessed periodically at follow-up visits to guide treatment plans. The clinician integrates the Quotient® report with information from other assessment tools and the clinical evaluation to help guide the discussion on the treatment plan. For more information please visit: http://www.biobdx.com/products
About BioBehavioral Diagnostics Company
BioBDx manufactures and markets the Quotient System, a tool that aids in the objective and accurate assessment of neural control functions related to deficits in inhibitory control. We are dedicated to providing physicians, parents and patients high-value information to guide personalized strategies and enhance quality of life for patients with ADHD. Our vision is to provide accurate tools for the diagnosis and management of neurological and psychiatric conditions, leading to a transformation of behavioral medicine. Founded in 2006, BioBDx is a privately held company.
Contacts:
|
BioBDx Byron Hewett Chairman and Chief Executive Officer 484-532-2201 |
Media/Investors: Tiberend Strategic Advisors, Inc. Claire Sojda 212-827-0020 |
SOURCE BioBehavioral Diagnostics Company
Share this article